2.1
Cabozantinib (Cabometyx, Ipsen) with nivolumab (Opdivo, Bristol Myers Squibb) is indicated for 'the first-line treatment of advanced renal cell carcinoma in adults'.
2 Information about cabozantinib with nivolumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for cabozantinib.
Price
2.3
The list price of cabozantinib is £5,143.00 per 30 20-mg, 40-mg or 60-mg tablets (excluding VAT; BNF accessed September 2023). Costs may vary in different settings because of negotiated procurement discounts.
2.4
The list price of nivolumab is £439.00 per 10 mg vial for infusion, £1,317.00 per 120 mg vial for infusion and £2,633.00 per 240 mg vial for infusion (excluding VAT; BNF accessed September 2023). Costs may vary in different settings because of negotiated procurement discounts.
2.5
The companies have commercial arrangements. These make cabozantinib and nivolumab available to the NHS with discounts. The size of the discounts are commercial in confidence. It is the companies' responsibility to let relevant NHS organisations know details of the discount.